Search

Author/Creator Patel, M R

1. 1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX). (23rd October 2018)

Authors:
Hecht, J R; Naing, A; Falchook, G S; Patel, M R; Aljumaily, R; Wong, D J; Autio, K A; Wainberg, Z A; Javle, M; Bendell, J; Pant, S; Hung, A; Oft, M; Leveque, J; Papadopoulos, K P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1144PResponses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors. (23rd October 2018)

Authors:
Garon, E B; Wong, D J; Schneider, J G; Aljumaily, R; Korn, W M; Patel, M R; Autio, K A; Papadopoulos, K P; Naing, A; Gabrail, N; Munster, P N; Goldman, J; Hung, A; Oft, M; Leveque, J; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1145PResponses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy. (23rd October 2018)

Authors:
Naing, A; Autio, K A; Falchook, G S; Meric-Bernstam, F; Litton, J K; Ibrahim, N K; Hung, A; Oft, M; Leveque, J; Patel, M R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1243TiPPhase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors. (23rd October 2018)

Authors:
Johnson, M L; Patel, M R; Ulahannan, S V; Hansen, A; George, B; Chu, Q S-C; Elgadi, M; Ge, M; Duffy, C; Graeser, R; Khedkar, S; Jones, S F; Burris, H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 1338PTracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy. (23rd October 2018)

Authors:
Merchan, J; Patel, M R; Powell, S F; Strauss, J; Cripe, T P; Old, M O; Diaz, R M; Russell, S J; Bexon, A S; Suksanpaisan, L; O'Connor, M K; Peng, K W
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Incidence and risk factors for major bleeding events in atrial fibrillation patients on direct oral anticoagulant therapy: data from the National Patient-Centered Clinical Research Network. (3rd October 2022)

Authors:
Arps, K; Harrington, J; Carnicelli, A P; Wu, A; Chiswell, K; Chamberlain, A M; Chrischilles, E; Jones, W S; Raj, V; Steinberg, B A; Mundl, H; Viethen, T; Granger, C B; Piccini, J P; Patel, M R
Journal:
European heart journal
Issue:
Volume 43(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗